Skip to content
Screener

Jazz Pharmaceuticals JAZZ Cash & Equivalents

Cash & Equivalents at other companies

Amgen logo
AmgenAMGN
$574M+5.9%
Alkermes logo
AlkermesALKS
$511.53M-1.9%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$119.53M-11.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$474.76M+201%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$127.64M+78.4%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Cash.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCash and Cash EquivalentsInvestments
Cash$667.5——$667.5$667.5—
Time deposits1,090.0——1,090.060.01,030.0
Money market funds1,116.8——1,116.81,116.8—
Totals$2,874.3——$2,874.3$1,844.3$1,030.0

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's cash & equivalents?
Jazz Pharmaceuticals (JAZZ) reported cash & equivalents of $667.5M in Q1 2026.
How has Jazz Pharmaceuticals's cash & equivalents changed year-over-year?
Jazz Pharmaceuticals's cash & equivalents decreased by 64.1% year-over-year, from $1.86B to $667.5M.
What is the long-term trend for Jazz Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's cash & equivalents has grown at a -8.4% compound annual growth rate (CAGR), from $1.06B to $682.7M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Jazz Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude